Sort   by:  
 Page size 
UnknownSafety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
Not available
S-EPMC3226526 | biostudies-literature
UnknownModified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis.
Not available
S-EPMC7077779 | biostudies-literature
UnknownThe Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis.
Not available
S-EPMC4251190 | biostudies-literature
UnknownClinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Not available
S-EPMC6585288 | biostudies-literature
UnknownIdentification of the NF-κB activating protein-like locus as a risk locus for rheumatoid arthritis.
Not available
S-EPMC3686260 | biostudies-literature
UnknownSafety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Not available
S-EPMC4316868 | biostudies-literature
UnknownRapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
Not available
S-EPMC3003523 | biostudies-literature
Sort   by:  
 Page size